Lipids Update: Current Guidelines for Lipid Management

Scripps Health

S. R. Mehta

Lipid Lowering Therapies: Where Did We Start, Where We Are Now and W…

The Texas Heart Institute

S. Virani

Inside the Studio with Drs. Joseph Rogers and Salim Virani - Current…

The Texas Heart Institute

J. Rogers, S. Virani

Non-Statin Pharmacotherapies for Risk Reduction

Scripps Health

M. Wilkinson

The Targets and Upcoming Medications for Dyslipidemia

Norman Lepor

Can We Cure Arteriosclerosis? New Thoughts and Concepts and New Game…

Cardiovascular Disease Management - 4th Annual Symposium

Non-Statin Therapies for Elevated LDL-C: The Role of Inclisiran (and…

Canadian Collaborative Research Network

J. Genest

Ambulatory Blood Pressure Monitoring

William White

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Lp(a): When to Measure it and What to Do About it

Canadian Collaborative Research Network

M. O'Donoghue

CT Coronary Calcium Scoring, Hard Plaque and Soft Plaque Visualizati…

Scripps Health

M. Budoff

Should Colchicine Become Standard Therapy for CAD?

Canadian Collaborative Research Network

P. Ridker

Role of Coronary Calcification and Risk Stratification

The Texas Heart Institute

E. Hernandez

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

ACC 2023: Management of Statin Side Effects and How to Keep Them on …

ACC 2023 Conference Coverage

J. Saseen

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray